Teva

Study Shows How Pharmaceutical Companies Maneuver To Maintain Sales, High Prices

This article is for premium subscribers. Please sign up here for a tax-deductible subscription. 

If you're a premium subscriber, sign in below. 

When a generic multiple sclerosis drug hit the U.S. market in 2015, observers expected it could push down prices in a class of drugs that has skyrocketed in recent years. 

That did not happen. 

Subscribe to Teva